Combination treatment for advanced solid tumors using Trametinib, Everolimus, and Lenvatinib

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of a combination therapy using Trametinib, Everolimus, and Lenvatinib for patients with recurrent or refractory advanced solid tumors, including hepatocellular carcinoma. The study aims to measure tumor diameter and evaluate the efficacy of the treatment regimen after administration. Participants will be monitored for their response to the therapy, providing valuable data on its potential benefits and effectiveness.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Recurrent/Refractory advanced solid tumors
* Age between 18 and 85 years
* Expected life expectancy is greater than three months

Exclusion Criteria:

* Benign tumor
* Life expectancy is less than three months
* Serious medical commodities
* others

Where it's running

• The Second Affiliated Hospital of Guangzhou Medical University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Zhenfeng Zhang, MD, PhD — Second Affiliated Hospital of Guangzhou Medical University
• Study coordinator: Zhenfeng Zhang, MD, PhD
• Email: zhangzhf@gzhmu.edu.cn
• Phone: +862039195966

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer

  This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.

  Recruiting at 2 sites Phase 3 BeOne Medicines · South Brisbane, Queensland and 1 other locations · NCT07836530

• Durvalumab + Tremelimumab with or without Lenvatinib for unresectable liver cancer

  This trial tests whether adding lenvatinib to the STRIDE regimen (durvalumab plus tremelimumab) helps people with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

  Recruiting at 13 sites Phase 2 Canadian Cancer Trials Group · Calgary, Alberta and 12 other locations · NCT06880523

• Treatment for ruptured liver cancer using TACE, Lenvatinib, and PD-1 inhibitors

  This study is testing a new treatment that combines a special type of chemotherapy with Lenvatinib and PD-1 inhibitors to see if it can help patients with serious liver cancer that has ruptured.

  Recruiting Sun Yat-sen University · Beijing, None Selected · NCT06740370

• Combining TIPS with Lenvatinib and PD-1 inhibitors for advanced liver cancer with portal vein tumor thrombus

  This study is testing if combining a special procedure with two cancer treatments can help people with advanced liver cancer and a serious blood clot in the portal vein feel better and have better results.

  Recruiting Sun Yat-sen University · Beijing, None Selected · NCT06622031

• Triple therapy for advanced liver cancer with bile duct tumor thrombus

  This study is testing a new combination treatment for people with advanced liver cancer that has spread to the bile ducts to see if it can help them when surgery isn't an option.

  Recruiting Fujian Provincial Hospital · Fuzhou, Fujian and 5 other locations · NCT06602011

• Treatment for advanced liver cancer using Cadonilimab and Lenvatinib

  This study is testing if a new combination of Cadonilimab, Lenvatinib, and chemotherapy can help people with advanced liver cancer that can't be surgically removed.

  Recruiting Phase 2 Hunan Cancer Hospital · Changsha, Hunan · NCT06406634

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.